Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
== Research == As of October 2025, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia and Alzheimer's disease. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals. Seltorexant is being explored at doses of 5 to 80 mg. In the early clinical trials conducted so far, seltorexant has been found to improve depression scores on the Hamilton Depression Rating Scale in people with MDD and to improve sleep onset, total sleep time, time awake after sleep onset, and sleep efficiency in people with MDD and/or insomnia.
His Pan-Slavic views were unleashed in this book, where he stated that the land of Slovaks should be annexed by the Tsar's empire and that eventually, the population could be not only Russified, but also converted into the rite of Orthodoxy, religion originally spread by Cyril and Methodius during the times of Great Moravia, which served as an opposition to the Catholic missionaries from the Franks. After the Hungarian invasion of Pannonia, Hungarians converted into Catholicism, which effectively influenced the Slavs living in Pannonia and in the land south of the Lechs. However, the Russian Empire often claimed Pan-Slavism as a justification for its aggressive moves in the Balkan Peninsula of Europe against the Ottoman Empire, which conquered and held the land of Slavs for centuries. This eventually led to the Balkan campaign of the Russian Empire, which resulted in the entire Balkan being liberated from the Ottoman Empire, with the help and the initiative of the Russian Empire. Pan-Slavism has some supporters among Czech and Slovak politicians, especially among the nationalistic and far-right ones, such as People's Party – Our Slovakia. The creation of an independent Czechoslovakia made the old ideals of Pan-Slavism anachronistic. Relations with other Slavic states varied, sometimes being so tense it escalated into an armed conflict, such as with the Second Polish Republic where border clashes over Silesia resulted in a short hostile conflict, the Polish–Czechoslovak War. Even tensions between Czechs and Slovaks had appeared before and during World War II.
=== As NCCAM (1998–2014) === In 2008 Josephine Briggs was appointed as director of NCCAM. She was "a nephrologist with impeccable scientific credentials". The appointment was considered surprising since she did not have a complementary and alternative medicine background or integrative medicine background. Writing for Science-Based Medicine, David Gorski states Briggs was in an impossible position: "She was a real scientist trying to impose scientific rigor on an enterprise that was inherently resistant to such an imposition." She attempted to impose a more scientific approach with two long-term strategic plans. The plans used "one of the most harmful tactics of quacks to legitimize their quackery under the banner of 'integrative medicine,' the co-opting of the opioid crisis as an excuse to claim all nonpharmacological treatments for pain as being 'integrative.' The results are threatening great harm to chronic pain patients by misguided governments wanting to force them to undergo quack treatments like acupuncture as a means of getting them off opioids." However, she was able to eliminate studies on homeopathy and tried to counter anti-vaccine beliefs. Energy healing was "relegated to the fringes, if not eliminated". Most of the studies became centered around nutrition, exercise, pharmacognosy, "and other modalities within the realm of science-based medicine". In 2009, after 17 years of government testing for $2.5 billion, almost no clearly proven efficacy of alternative therapies had been found.
Vaginal films are soluble, thin sheets of medication that are inserted into the vagina where they dissolve and release the substances. Typical uses include delivery of contraceptive substances or antibiotics for infections. These films are inserted by simply pushing them into the vagina with one’s fingers. There they dissolve quickly upon interaction with natural vaginal fluids. Bioadhesives are substances that naturally stick to live tissue. Currently, studies are being done on bioadhesives adhering to cervical mucous membranes to allow for an extended release period. The drug would be released with mucus to create a localized treatment with high effectiveness. This is anticipated to be highly useful for treatment of cervical cancer. Bioadhesives can come in multiple forms, such as films, tablets, or gels. The appeal of bioadhesives is that they take advantage of the mucous environment surrounding the cervix and utilize it to benefit the drug delivery mechanism.
7-DHC can be produced by animals and plants via different pathways. It is not produced by fungi in significant amounts. It is made by some algae, but the pathway is poorly understood. Industrially, 7-DHC generally comes from lanolin, and is used to produce vitamin D3 by UV exposure. Lichen (Cladonia rangiferina) is used to produce vegan D3. 7-DHC is used for vitamin D3 synthesis via lanosterol in land animals, via cycloartenol in plants, and in algae together with another provitamin D ergosterol for D2. In fungi solely ergosterol is used for synthesis of D2 via lanosterol. Vitamin D Smith–Lemli–Opitz syndrome 7-Dehydrocholesterol reductase
Sources: en.wikipedia.org
=== 1998 Los Barrios, Cádiz, Spain === In the Acerinox accident of 1998, the Spanish recycling company Acerinox accidentally melted down a mass of radioactive caesium-137 that came from a gamma-ray generator.
=== Off-label drugs === Acetazolamide (Diamox) – carbonic anhydrase inhibitor Atomoxetine (Strattera) – norepinephrine reuptake inhibitor (NRI) Eszopiclone (Lunesta) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/Z-drug Oxybutynin (Ditropan) – muscarinic acetylcholine receptor antagonist (anticholinergic) Pimavanserin (Nuplaizid) – serotonin 5-HT2A receptor antagonist Sodium oxybate (GHB; Xyrem) – GABAB receptor agonist and GHB receptor agonist Trazodone (Desyrel) – various actions Weight-loss drugs (e.g., liraglutide, semaglutide) – obesity-related sleep apnea
The earliest kingdoms to emerge in Ghana were Bonoman in the south and the Kingdom of Dagbon in the north, with Bonoman existing in the area during the 11th century. From the 17th century, Akan states began to emerge from what is believed to have been the Bonoman area, mainly based on gold trading. These states included Bonoman (Brong-Ahafo region), Adansi and Asante (Ashanti Region), Denkyira (Western North region), Mankessim Kingdom (Central region), Akyem and Akwamu (Eastern region). By the 19th century, the territory of the southern part of Ghana was included in the Asante Kingdom. The government of the Ashanti Empire operated first as a loose network and eventually as a centralised kingdom with a specialised bureaucracy centred in the capital city of Kumasi. Prior to Akan contact with Europeans, the Akan people created an economy based on principally gold and gold bar precious metals, which were traded with other states in Africa. The Ga-Dangme migrated westward from south-western Nigeria. The Ewe, formerly known as Dogbo, migrated from Ketu (Benin) area with their Gbe-speaking kinsmen (Adja, Fon, Phla/Phera and Ogun/Gun) and, in transition, settled at Tado in Togo, and Dogbo Nyigbo in Benin Republic, with Nortsie (a walled town in what later is Togo) as their final dispersal point. Their dispersal from Nortsie was necessitated by the high-handed rule of King Agorkorli (Agɔ Akɔli), who was the reigning monarch of the tribe at that time.
=== pH-responsive nanogels === pH responsive nanogels are an attractive form of nanogel technology due to the different pH levels found within the body. Healthy tissues exhibit a pH of 7.4 whereas tumors can be as low as 6.5 and the stomach as low as 1.0. The protonation or deprotonation of certain functional groups can change the swelling rate and stability of a nanogel, thus resulting in the release of encapsulated cargo when exposed to different pH ranges. For example, anionic nanogels with carboxylic acid groups will collapse upon exposure to a pH that is smaller than the pKa of the nanogel polymer. Similarly, cationic nanogels with terminal amino groups will become protonated if the pH of the environment is less than the pKa of the hydrogel. In this case, the swelling rate of the nanogel will change and it will become more hydrophilic. Other groups have also previously cross-linked pH-responsive hydrazone linkages to polysaccharide-based nanogels that released a payload in an acidic environment.
=== Hungary and the Pan-European Picnic === Events in Poland were soon followed by developments in Hungary, where reformist leaders dismantled border controls with Austria during the summer of 1989. An opening of a border gate once part of the Iron Curtain between Austria and Hungary triggered a chain reaction, at the end of which the German Democratic Republic no longer existed and the Eastern Bloc had disintegrated—incentivized at least in part by the absence of Soviet intervention. The idea for the Pan-European Picnic came from Otto von Habsburg and was intended as a test of whether the Soviet Union would react when the iron curtain was opened. The Pan-European Union Austria then advertised with leaflets in Hungary to make East Germans aware of the possibility of escape. The result was the greatest mass exodus since the building of the Berlin Wall and the non-reaction of the Eastern bloc states showed the oppressed population that their governments had lost absolute power. Subsequently, large numbers of East German refugees attempted to flee through Hungary and the weak reactions showed that the communist leaders lost even more power, which also contributed directly to the collapse of communist rule in East Germany. By mid-1989 even Soviet officials openly joked that Eastern European states would now be allowed to proceed in their own way (like Sinatra), signaling the end of enforced ideological conformity within the bloc.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.